Skip to main navigation
  • Careers
  • Contact

Menu

Skip to content
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • SEC Filings
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Estimates
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • ADCs
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • ZTlido™
      • RTX
  • Translational Efficiencies

News Releases

fundamentals sub menu

  • Fundamentals

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis

May 26, 2020

Sorrento Enters Into Binding Term Sheet to Acquire Exclusive Rights to Abivertinib with Completed Registrational Trial Data in Non-Small Cell Lung Cancer

May 21, 2020

STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies

May 15, 2020

Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELD™ Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19)

May 08, 2020

SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS

Apr 02, 2020

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

Mar 31, 2020

Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program

Mar 25, 2020

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Mar 24, 2020

SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

Mar 23, 2020

SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

Mar 20, 2020

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Email Page
Clinical Trials
clinicaltrials@sorrentotherapeutics.com
Investors
investors@sorrentotherapeutics.com
Business Development
business@sorrentotherapeutics.com
Media Requests
mediarelations@sorrentotherapeutics.com
© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • DMCA
  • Trademarks
  • Linking Policy
  • LinkedIn
MENU
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Analyst Coverage
      • Estimates
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • Quarterly Results
      • Fundamentals
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Investor Contact
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • Antibody Drug Conjugates (ADCs)
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • RTX
      • ZTlido™
  • Translational Efficiencies
  • Careers
  • Contact